The State University of New York Trials

The State University of New York	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Ionita, Cristian

PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting

1633

Europe, Japan, US, RoW

Lasmiditan, LY573144, Placebo

Eli Lilly and Company

Migraine

01/25

PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting

1000

Europe, Japan, US, RoW

Lasmiditan, LY573144

Eli Lilly and Company

Migraine

03/26

NCT04174157: Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Recruiting

N/A

700

Europe, Japan, US, RoW

Prospective observational registry, Zolgensma

Novartis Pharmaceuticals, United BioSource, LLC

Spinal Muscular Atrophy (SMA)

06/38

Pol, Christine

HOPE-3, NCT05126758: A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Active, not recruiting

104

Deramiocel (CAP-1002), Cardiosphere-Derived Cells (CDCs), Placebo

Capricor Inc.

Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases

12/25

12/27

RESILIENT, NCT05337553 / 2022-000193-25: A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

Active, not recruiting

269

Europe, US, RoW

taldefgrobep alfa, BHV-2000, BMS-986089, Placebo

Biohaven Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Inc, Biohaven Pharmaceuticals, Inc.

Spinal Muscular Atrophy, Neuromuscular Diseases, SMA

01/25

RISE 2, NCT06132893: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Recruiting

2/3

390

Europe, US, RoW

BHV-7000, Placebo

Biohaven Therapeutics Ltd.

Focal Epilepsy

08/25

09/25

NCT03320018: Neuroprotection in Acute Ischemic Stroke

Completed

2/3

Hydrogen, H2, Minocycline, Minocin, Minomycin, Akamin, Placebo Hydrogen, Placebo Minocycline

Stony Brook University

Stroke, Ischemic

08/19

HEALEY ALS, NCT04297683: Platform Trial - Master Protocol

Active, not recruiting

2/3

1500

ABBV-CLS-7262, DNL343

Merit E. Cudkowicz, MD, Massachusetts General Hospital

Amyotrophic Lateral Sclerosis

07/25

04/26

NCT04175301: Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.

Active, not recruiting

Hydrogen, H2, Placebo oral tablet

Stony Brook University

Malignant Glioma

07/25

08/25

NCT06401564: Virtual Reality Based Rehabilitation After Ischemic Stroke

Recruiting

N/A

Virtual Reality Therapy

Stony Brook University, Good Samaritan Hospital

Ischemic Stroke

12/25

12/26

NCT06069934: Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2)

No Longer Available

N/A

Pridopidine

Prilenia, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)

Amyotrophic Lateral Sclerosis

NCT04174157: Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Recruiting

N/A

700

Europe, Japan, US, RoW

Prospective observational registry, Zolgensma

Novartis Pharmaceuticals, United BioSource, LLC

Spinal Muscular Atrophy (SMA)

06/38

Treidler, Simona

HOPE-3, NCT05126758: A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Active, not recruiting

104

Deramiocel (CAP-1002), Cardiosphere-Derived Cells (CDCs), Placebo

Capricor Inc.

12/25

12/27

NCT04174157: Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Recruiting

N/A

700

Europe, Japan, US, RoW

Prospective observational registry, Zolgensma

Novartis Pharmaceuticals, United BioSource, LLC

Spinal Muscular Atrophy (SMA)

06/38



	Diseases Companies Products Productz Mechanisms of Action Sites